CO6501124A2 - Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas - Google Patents

Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas

Info

Publication number
CO6501124A2
CO6501124A2 CO12095471A CO12095471A CO6501124A2 CO 6501124 A2 CO6501124 A2 CO 6501124A2 CO 12095471 A CO12095471 A CO 12095471A CO 12095471 A CO12095471 A CO 12095471A CO 6501124 A2 CO6501124 A2 CO 6501124A2
Authority
CO
Colombia
Prior art keywords
present
polypeptides
relates
cancer
sequence
Prior art date
Application number
CO12095471A
Other languages
English (en)
Inventor
Portilla Tania Carmenate
Martinez Karina Garcia
Pereira Gabriel Marquez
Roche Diamile Gonzalez
Rodriguez Samuel Perez
Davila Agustin Bienvenido Lage
Original Assignee
Centro Inmunologia Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43646474&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6501124(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Centro Inmunologia Molecular filed Critical Centro Inmunologia Molecular
Publication of CO6501124A2 publication Critical patent/CO6501124A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Abstract

La presente invención se relaciona en general con polipéptidos cuya secuencia primaria tiene una alta homología con la secuencia de la Interleucina 2humana(IL-2) con algunas mutaciones puntuales en la secuencia de la IL-2nativa. Los polipéptidos de la presente invención tienen un efecto inmunomodulador sobre el sistema inmune, que es selectivo/preferencial sobre célulasT reguladoras. La presente invención también se relaciona con polipéptidos específicos cuya secuencia de aminoácidos es divulgada en la presente invención. En otro aspecto la presente invención se relaciona con las composiciones farmacéuticas que comprenden como principio activo los polipéptidos divulgados. Por último la presente invención se relaciona con el uso terapéutico de los polipéptidos y composiciones farmacéuticas divulgados dado su efecto modulador del sistema inmune sobre patologías como cáncer y enfermedades infecciosas crónicas.
CO12095471A 2009-11-27 2012-06-06 Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas CO6501124A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20090203A CU23734A1 (es) 2009-11-27 2009-11-27 Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas

Publications (1)

Publication Number Publication Date
CO6501124A2 true CO6501124A2 (es) 2012-08-15

Family

ID=43646474

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12095471A CO6501124A2 (es) 2009-11-27 2012-06-06 Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas

Country Status (24)

Country Link
US (1) US8759486B2 (es)
EP (1) EP2505206B1 (es)
JP (1) JP5680661B2 (es)
KR (1) KR101484590B1 (es)
CN (1) CN102665754B (es)
AR (1) AR079197A1 (es)
AU (1) AU2010324254B2 (es)
BR (1) BR112012012025B8 (es)
CA (1) CA2781173C (es)
CL (1) CL2012001030A1 (es)
CO (1) CO6501124A2 (es)
CU (1) CU23734A1 (es)
EA (1) EA021867B1 (es)
EC (1) ECSP12011803A (es)
ES (1) ES2643465T3 (es)
HK (1) HK1169961A1 (es)
MX (1) MX2012006077A (es)
MY (1) MY162324A (es)
NZ (1) NZ599792A (es)
PE (1) PE20121636A1 (es)
SG (1) SG181089A1 (es)
TN (1) TN2012000182A1 (es)
WO (1) WO2011063770A2 (es)
ZA (1) ZA201203762B (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10781242B2 (en) 2013-09-24 2020-09-22 Medicenna Therapeutics Inc. Interleukin-2 fusion proteins and uses thereof
CN106794230A (zh) 2014-03-17 2017-05-31 德意志联邦共和国代表主席罗伯特·科赫研究所 用于诱导或延长细胞之细胞毒性免疫应答的方法的药物
WO2015164815A1 (en) 2014-04-24 2015-10-29 The Board Of Trustees Of The Leland Stanford Junior University Superagonists, partial agonists and antagonists of interleukin-2
US20170157215A1 (en) 2015-12-04 2017-06-08 Jomoco, Corp. Compositions and methods to mitigate or prevent an immune response to an immunogenic therapeutic molecule in non-human primates
MX2019003543A (es) 2016-09-28 2019-06-17 Xoma Us Llc Anticuerpos que se fijan al interleucina-2 y sus usos.
CU24483B1 (es) * 2016-11-15 2020-04-02 Ct Inmunologia Molecular Método para incrementar los niveles de secreción de la interleucina-2
CA3056630A1 (en) 2017-03-15 2018-09-20 Pandion Therapeutics, Inc. Targeted immunotolerance
EP3630163A4 (en) 2017-05-24 2021-06-09 Pandion Operations, Inc. TARGETED IMMUNTOLERANCE
CA3067909A1 (en) 2017-06-19 2018-12-27 Medicenna Therapeutics Inc. Uses and methods for il-2 superagonists, agonists, and fusions thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
EA202092316A1 (ru) 2018-03-28 2021-05-25 Бристол-Маерс Сквибб Компани Слитые белки интерлейкина-2/альфа-рецептора интерлейкина-2 и способы применения
CN111918665A (zh) * 2018-03-28 2020-11-10 阿森迪斯药物肿瘤股份有限公司 Il-2缀合物
US20210253671A1 (en) * 2018-06-07 2021-08-19 Prottech Inc. Pharmaceutical Composition Containing Fusion Protein and Use Thereof
US20220403001A1 (en) 2018-06-12 2022-12-22 Obsidian Therapeutics, Inc. Pde5 derived regulatory constructs and methods of use in immunotherapy
MX2021014178A (es) 2019-05-20 2022-01-04 Pandion Operations Inc Inmunotolerancia dirigida a la molecula de adhesion celular de adresina vascular de mucosas (madcam).
WO2021146436A2 (en) 2020-01-14 2021-07-22 Synthekine, Inc. Biased il2 muteins methods and compositions
TW202214677A (zh) * 2020-09-04 2022-04-16 大陸商江蘇先聲藥業有限公司 Ｉｌ－２突變體及其應用
KR20230097094A (ko) 2020-10-29 2023-06-30 브리스톨-마이어스 스큅 컴퍼니 질환의 치료를 위한 융합 단백질
KR20240026905A (ko) 2021-04-30 2024-02-29 티젠 파마 에스에이 림프구의 단일 용기 확장
WO2023133595A2 (en) 2022-01-10 2023-07-13 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4853332A (en) 1982-10-19 1989-08-01 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins
US4959314A (en) 1984-11-09 1990-09-25 Cetus Corporation Cysteine-depleted muteins of biologically active proteins
US5116943A (en) 1985-01-18 1992-05-26 Cetus Corporation Oxidation-resistant muteins of Il-2 and other protein
JP3024311B2 (ja) 1991-10-03 2000-03-21 味の素株式会社 Ｉｌ−２受容体重鎖に結合するポリペプチド
US5229109A (en) 1992-04-14 1993-07-20 Board Of Regents, The University Of Texas System Low toxicity interleukin-2 analogues for use in immunotherapy
US5635597A (en) 1994-05-27 1997-06-03 Affymax Technologies, N.V. Peptides that bind IL-2 receptors
US6955807B1 (en) * 1998-05-15 2005-10-18 Bayer Pharmaceuticals Corporation IL-2 selective agonists and antagonists
US6168785B1 (en) 1998-07-16 2001-01-02 Institut Pasteur Biological applications of new peptides of IL-2 and derivatives and use as therapeutic agents
WO2000011028A2 (en) 1998-08-21 2000-03-02 Yeda Research And Development Co. Ltd. Anti-inflammatory peptides derived from il-2 and analogues thereof
WO2003048334A2 (en) 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
US7569215B2 (en) 2003-07-18 2009-08-04 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
AU2007271398B2 (en) * 2006-07-06 2013-06-20 Merck Patent Gmbh Compositions and methods for enhancing the efficacy of IL-2 mediated immune responses
US8906356B2 (en) * 2007-11-05 2014-12-09 Massachusetts Institute Of Technology Mutant interleukin-2 (IL-2) polypeptides
DE102008023820A1 (de) * 2008-05-08 2009-11-12 Aicuris Gmbh & Co. Kg Mittel zur Behandlung und/oder Prophylaxe einer Autoimmunerkrankung und zur Bildung von Regulatorischen T-Zellen

Also Published As

Publication number Publication date
MX2012006077A (es) 2012-09-07
CA2781173A1 (en) 2011-06-03
EP2505206B1 (en) 2017-09-27
US8759486B2 (en) 2014-06-24
CA2781173C (en) 2015-10-13
US20120315245A1 (en) 2012-12-13
CN102665754B (zh) 2014-03-12
JP2013512200A (ja) 2013-04-11
BR112012012025A2 (pt) 2016-05-17
AU2010324254A1 (en) 2012-05-31
EA021867B1 (ru) 2015-09-30
CL2012001030A1 (es) 2012-07-20
HK1169961A1 (en) 2013-02-15
ECSP12011803A (es) 2012-07-31
BR112012012025B1 (pt) 2021-05-11
TN2012000182A1 (en) 2013-12-12
MY162324A (en) 2017-05-31
EP2505206A2 (en) 2012-10-03
CN102665754A (zh) 2012-09-12
AR079197A1 (es) 2012-01-04
AU2010324254B2 (en) 2014-01-09
WO2011063770A3 (es) 2011-09-09
SG181089A1 (en) 2012-07-30
ZA201203762B (en) 2013-01-30
NZ599792A (en) 2014-01-31
PE20121636A1 (es) 2012-12-03
ES2643465T3 (es) 2017-11-23
CU23734A1 (es) 2011-11-15
KR20120106728A (ko) 2012-09-26
KR101484590B1 (ko) 2015-01-22
BR112012012025B8 (pt) 2021-05-25
EA201290395A1 (ru) 2012-10-30
WO2011063770A2 (es) 2011-06-03
JP5680661B2 (ja) 2015-03-04

Similar Documents

Publication Publication Date Title
CO6501124A2 (es) Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas
CU23923B1 (es) Polipéptidos derivados de la il-2 con actividad agonista
CY1119616T1 (el) Συζευγματα ανθρωπινου αντισωματος-φαρμακου κατα του ιστικου παραγοντα
BR112012020839A2 (pt) vacinas para uso na profilaxe e tratamento de doença de vírus da influenza
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
CY1118496T1 (el) Φαρμακεyτικες συνθεσεις
BR112016012538A2 (pt) peptídeos citotóxicos e conjugados dos mesmos
BR112015014462A2 (pt) vetorização farmacêutica de uma via de sinalização de dinucleotídeos cíclicos de mamíferos
BR112016026291A2 (pt) Derivados do ácido borônico e usos terapêuticos dos mesmos
CR20160117A (es) Anticuerpos contra el inhibidor del activador de plasminógeno tipo 1 (pai-1) y usos de los mismos
BR112015011179A8 (pt) composições farmacêuticas aquosas estáveis compreendendo insulina humana ou um análogo ou derivado das mesmas, seu uso e processos para sua preparação
CL2008003480A1 (es) Compuestos derivados de amino-pirimidina, con propiedades inmunomoduladoras y que actuan a traves de tlr7; proceso para preparar los compuestos; compuestos intermediarios; composicion y combinacion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos
UY29395A1 (es) Formulación de medicamentos conteniendo vardenafilo.
BR112016010383A2 (pt) compostos de pyy seletivos e usos dos mesmos
UY32315A (es) Compuestos de piperidina y usos de los mismo-596
CL2012001836A1 (es) Compuestos de pirazol, antagonista de crth2; composicion farmacéutica; uso en el tratamiento de trastornos inflamatorios, infecciosos, inmunoreguladores, enfermedades respiratorias, gastrointestinales o dolencias, entre otros.
CO6410278A2 (es) Disoluciones pediátricas que continen un beta-bloqueante
BR112016020181A8 (pt) composições de ácido lipoico éster colina e métodos de uso.
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
BR112012013164A2 (pt) composições farmacêuticas para o estímulo de células-tronco
CR20140475A (es) Agentes terapéuticos para administración subcutánea optimizados
BR112015013125A2 (pt) tratamento de lesões orais usando composições de matrix placentário extracelular
BR112018016715A2 (pt) ?formulações de oritavancina?
BR112015022730A2 (pt) formulações de rfviii, método para conjugação covalente de rfviii com um polímero biocompatível e uso de rfviii no preparo de formulação de rfviii para tratamento de hemofilia a
BR112016012435A8 (pt) vacina, e, usos de uma proteína orf2 recombinantemente expressada do circovírus porcino tipo 2

Legal Events

Date Code Title Description
FC Application refused